Startups
Locate Bio Limited today announces that it has changed its name from Locate Therapeutics Limited and received a new direct investment of £0.5 million from Mercia Technologies PLC (AIM: MERC) (“Mercia”).
Execs at Novo Nordisk, AbbVie, and more made moves this week. Here’s a roundup of those changes.
Karolinska Development’s portfolio company Phamanest changes its name to Palette Life Sciences. The company also announces a global licensing agreement with Nestlé Skin Health.
TIME Magazine came out with a list of the 50 most influential people in healthcare, dubbed The Health Care 50. A look through the list shows just how many ties and connections—as well as influence—this group has on the biopharma industry.
San Mateo, Calif.-based startup CuraSen Therapeutics surged forward this morning with $54.5 million in Series A funding and a leadership team that includes executives from Afferent Pharmaceuticals, a company acquired by Merck in 2016 for $1.2 billion.
Taiho Ventures, the corporate venture capital arm of Taiho Pharmaceutical, has pumped up its venture capital pool from $50 million to $300 million. It also indicates it plans to accelerate its “open innovation” through the investments.
Discovery Life Sciences, a leading research biobank located in Los Osos, California, recently got much, much bigger via a four-company merger. Ann Dover, Discovery’s founder, president and CEO, took time to speak with BioSpace about the merger and the new identity of the company.
Gotham Therapeutics launched in New York with a $54 million Series A financing. The focus is on a subgroup of RNA metabolism called epitranscriptomics. This involves the biochemical modifications of RNA within a cell, which have an impact on gene expression.
A new biopharmaceutical company known as Sitryx launched with $30 million in a Series A funding round to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation.
The Alliance to Protect Medical Innovation (APMI) will educate the public about medical breakthroughs and fact-check policies that would limit lifesaving cures and treatments
PRESS RELEASES